|Aqua Bounty Technologies Inc.
||COM SHS USD0.001 (REG S)
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
|goz1986: I am not at all upset about the company. I feel they have done everything they can to get approval and reduce the dilution to the share price.......
To be fair if I was the Georgian I would be doing the same thing. We are going to be on our knees by December with the begging bowl.|
|goz1986: If this does get a favourable review from the FDA it is going to be all over the papers which will have a cracking knock on effect on the share price....|
|bronislav: lufc.what if news comes and its favourable,then there is a demand for shares.where will the share price go/?|
|goz1986: To raise approximately GBP3.18 million ($5.0 million) before expenses by
means of a subscription of 17,666,666 new Common Shares by Linnaeus at a price
of 18 pence per share. The Subscription Price represents a 52.6% premium to the
volume weighted average share price of the Company for the 90 days ending on the
last business day prior to the announcement of the Subscription.
I would like to think you don't give 3million to a firm you are concerned will not get permission for a GM slamon.... However, funnier things have happened.|
|lunartik: Sunday Times
The chart shows the share price of Aqua Bounty, a company whose stock is leaping upwards like a salmon heading for its spawning ground.
A fitting simile, because Aqua Bounty, headquartered in Massachusetts but listed in London, is making what is likely to be the first genetically modified animal approved for human consumption.
Its salmon will grow much faster than a normal one, thanks to the introduction of a gene that keeps growth hormones switched on at all time. Normal salmon take a break every now and then.
On Friday, the firm passed another milestone when America's Food and Drug Administration said meat from the modified fish was essentially the same as ordinary salmon. The next big test is a hearing at the end of the month.
Meanwhile, in Belgium they are working on the Enviropig - which has less polluting poo - and in America there are bovines that shrug off mad cow disease. Investors face two questions: how do they pick the winners, and how do they gauge public reaction? Protesters are already decrying the "Frankenfish". Shareholders must work out if the likely FDA approval outbalances the risk that the public will say no to buying GM food.|
|waldron: Aqua Bounty Technolo Aqua Bounty knows no reason for share price fall; still sees 2006 loss in line
LONDON (AFX) - Aqua Bounty Technologies Inc said it is unaware of any
operational reason for the recent sharp fall in its share price.
The biotechnology firm affirmed that its 2006 full-year loss will be in line
with expectations, and that it will miss revenue forecasts for 2007, as it had
earlier stated in a trading update on March 9.
It said its financial health is excellent.
In last month's statement, the company said the full-year loss was due to
the slow pace of regulatory approval in target markets for its lead product,
Shrimp IMS, an immunostimulant deployed as a feed additive.
Aqua Bounty will release its results for the year ended Dec 31, 2006 in May.
At 8.35 am, shares in Aqua Bounty were up 1/2 pence at 30-1/2, having fallen
from around 83 pence at the beginning of March. The company floated on AIM in
March last year at 148 pence.
Aqua Bounty share price data is direct from the London Stock Exchange